跳到正文
ISPE iSpeak 专家博客·· 5 天前AI 评分24

ISPE 2026 Pharma 4.0™与生物制药大会专题:自动化能否补上细胞与基因治疗生产的缺口?

Is Automation the Missing Link in Cell and Gene Therapy Manufacturing?

AI 导读

ISPE 2026 Pharma 4.0™与生物制药大会将于2026年12月10-11日在柏林举行,会议设“Pharma 4.0™ in Action:生物制药生产转型”分场,探讨自动化能否弥合细胞与基因治疗创新与商业化之间的差距。

正文 · 原文

As pharmaceutical manufacturers look for ways to expand capacity while maintaining product quality and regulatory compliance, many are asking a critical question: Can automation help bridge the gap between innovation and commercialization?

That question sits at the center of "Is Automation the Missing Link in Cell and Gene Therapy?", a session in the Pharma 4.0™ in Action: Biopharma Manufacturing Transformation Track at the 2026 ISPE Pharma 4.0™ and Biopharma Conference, taking place 10-11 December 2026 in Berlin, Germany.

Why Cell and Gene Therapy Manufacturing Needs a New Approach

The rapid growth of cell and gene therapies has exposed a significant challenge across the industry: manufacturing processes often remain highly manual.

Producing a single CAR-T batch can require more than a dozen operators, and that figure does not include environmental monitoring personnel, quality control teams, warehouse staff, or other support functions. The result is a manufacturing model that can be expensive to scale, labor-intensive to operate, and difficult to replicate consistently across facilities.

While tremendous scientific progress has been achieved, manufacturing capacity has not always kept pace.

This challenge reflects a broader industry trend that many organizations are currently facing. Conversations about automation, robotics, artificial intelligence (AI), and digital manufacturing are increasingly common, yet many facilities still rely on manual processes and disconnected systems.

According to session speaker Faryal Khan, Lead Process Engineer at CRB, the challenge is no longer determining what technology can do.


The question is no longer what technology can do. Its capabilities are well established. The more important question is how pharmaceutical manufacturers can successfully implement these technologies and make them work effectively in practice by 2027.

That practical implementation focus is a defining theme of this year's conference and of the Pharma 4.0™ in Action track.

Learning From Real-World CAR-T Manufacturing Facilities

Rather than focusing on theoretical possibilities, this session examines real-world manufacturing experience.

Attendees will hear lessons learned from two autologous CAR-T facilities that pursued very different operational models.

One facility relied primarily on manual operations and encountered familiar challenges, including:

  • High full-time employee requirements
  • Quality control bottlenecks
  • Significant operational complexity
  • Unsustainable cost-per-dose economics

A second facility pursued a different strategy, implementing selective automation, robotics, and smart manufacturing principles to reduce labor demands while maintaining product integrity and quality expectations.

By comparing these approaches, the session explores where automation delivers the greatest value and where human expertise remains essential.

The result is a practical discussion grounded in operational reality rather than technology hype.

How Automation Supports Scalable Cell and Gene Therapy Manufacturing

Many organizations view automation as a way to reduce labor. However, the session takes a broader perspective.

Automation can help address several persistent manufacturing challenges, including:

  • Process consistency
  • Manufacturing scalability
  • Facility utilization
  • Data collection and visibility
  • Workflow coordination
  • Deviation reduction
  • Quality oversight

When implemented thoughtfully, automation can also allow skilled personnel to focus on higher-value activities rather than repetitive manual tasks.

This philosophy aligns closely with the broader goals of Pharma 4.0™, which emphasizes the integration of people, processes, and technology through trusted data ecosystems and connected operations.

Rather than replacing human expertise, automation can augment it, enabling operators, engineers, and quality professionals to make better-informed decisions while improving overall system performance.

Bringing Pharma 4.0™ Into Practice

One of the strengths of the Pharma 4.0™ in Action: Biopharma Manufacturing Transformation track is its emphasis on implementation.

The track bridges the gap between digital strategy and operational execution by showcasing how organizations are applying trusted data, advanced analytics, AI, and integrated robotics across the biopharmaceutical manufacturing lifecycle.

For attendees working in advanced therapy medicinal products, biologics, plasma fractionation, or aseptic manufacturing, these sessions provide valuable examples of how digital transformation initiatives are being applied in real-world environments.

Khan notes that many of the innovations discussed throughout the industry only a few years ago are now becoming reality.

From robotics-enabled manufacturing systems to smarter facilities and new approaches to data utilization, organizations are beginning to demonstrate what successful implementation looks like in practice.

That makes opportunities to learn directly from practitioners especially valuable.

Why This Session Matters

For organizations investing in cell and gene therapy manufacturing, the stakes are high.

Manufacturing decisions made today will influence scalability, facility costs, workforce requirements, product quality, and ultimately patient access for years to come.

The session challenges a long-standing assumption that cell and gene therapy facilities must remain highly labor-intensive in order to succeed.

Instead, it explores how automation, robotics, and thoughtful facility design can work together to create more efficient and sustainable manufacturing models.

Perhaps most importantly, attendees will gain practical insights from professionals who have already navigated these challenges. Understanding what worked, what did not, and what organizations would do differently can help accelerate future projects and reduce implementation risk.

As Khan emphasizes, even a single lesson that prevents a costly mistake or improves operational performance can provide significant value.

Join the Conversation in Berlin

The 2026 ISPE Pharma 4.0™ and Biopharma Conference will bring together leaders from across the pharmaceutical and biopharmaceutical industries to explore how digital technologies, automation, AI, and data-driven manufacturing are shaping the future of healthcare production.

For professionals involved in cell and gene therapy manufacturing, "Is Automation the Missing Link in Cell and Gene Therapy?" offers a timely opportunity to examine one of the industry's most pressing challenges through the lens of practical experience and real-world implementation.

Whether evaluating new facility designs, planning automation investments, or seeking ways to improve manufacturing scalability, attendees will leave with actionable insights that can be applied within their own organizations.

Register Today

来源:ISPE iSpeak 专家博客 · ispe.org